Latest news on alleged patent infringement in the Netherlands

this announcement is made in accordance with Rule 13.09 (1) of the Listing RulesAs disclosed in the 2007 Announcement, the group member company concerned is involved in the lawsuit brought by the plaintiff to the group member company concerned, alleging that the group member company concerned violated the relevant patent by submitting the sale, import and/or sale of L-Lysine products in the Netherlands, and that the court had issued the judgment, ruling that the group member company had infringed some of the relevant patents, but had not violated any trade secrets as the plaintiff allegedly didthe group member company concerned has appealed the judgement to the Court of Appeal of The HagueOn 7 April 2011, the Company received an English translation of the provisional decision of the Court of Appeal in The Hague dated 29 March 2011 and upheld the judgement pending a further non-trial hearing on legal costs, which is now scheduled for May 13, 2011The Board considered that the group member companies concerned had reason to appeal against the decision of the Court of Appeal of The HagueHowever, the Board is now seeking legal advice on the feasibility of appealing the decisionHowever, there is no guarantee that the outcome of the action will be in the interest of the Group Member Company in question if an appeal is madeCaution must be exercised when trading the Company's securities by shareholders and interested investors-----------------------------------------------------------------------------------------this announcement is made in accordance with section 13.09 (1) of the Securities Listing Rules of the Stock Exchange of Hong Kong Limited ("Listing Rules")hereby referring to the announcement made on 22 August 2007 by Dentons Biochemical Technology Group Limited ("the Company", together with its subsidiary, the Group) on 22 August 2007 (the "2007 Announcement")As disclosed in the 2007 Announcement, the Company and its other wholly owned subsidiaries ("relevant Group Member Companies") are involved in a project between Ajinomoto Co., Incand Ajinomoto Eurolysine S.A.S("Plaintiff") filed a lawsuit before the Local Court of The Hague on 15 May 2006 against the group member company concerned, according to which the group member company allegedly filed the sale, import and /or sale of its L-lysine products in the Netherlands, thereby infringing the Dutch part of the three European patents ("relevant patents") with the registration number of EP0.773710 (entitled "Processfor Producing L-Lysine Fermentation"), EP0.733.712 (titled "Processfor Production Production SubstanceS)") and EP0.796.912 (titled "New Lysine deglutinase Gene and Procedure for the Production of L-Lysine( Novel Lysine Decarboxylase Gene and Processfor Producing L-Lysine)The Hague District Court issued a judgment in August 2007 ("The Judgment" ) finding that the group member companies concerned had infringed two relevant patents, patent numbers EP0.773.710 and EP0.733.712, but had not violated any trade secrets as the plaintiff had allegedThe alleged infringement proceedings under patent number EP0.796.912 shall be adjourned pending a decision by the European Patent Office against the registration proceedingsthe group member company concerned has appealed the judgement to the Court of Appeal of The HagueOn 7 April 2011, the Company received an English translation of the provisional ruling of the Court of Appeal in The Hague dated March 29, 2011, upholding the judgment on the infringement of two patents and suspending the proceedings pending further non-trial hearing son-in-law on legal costs, which is now scheduled for May 13, 2011The alleged infringement proceedings under patent number EP0.796.912 will still have to be suspended pending a decision by the European Patent Office against the registration proceedingsthe Board of Directors (the Board of Directors) considers that the decision of the Hague Court of Appeal will not adversely affect the sale, financial or trade status and prospects of the Group as the Group has developed a bacterial variety of the same type of class that is different from the object of the action for the production of its L-lysine products and no longer uses the bacterial varieties involved in the proceedings to produce L-Lysine productsthe Board of Directors considered that the group member companies concerned had reason to appeal against the decision of the Court of Appeal of The HagueHowever, the Board is now seeking legal advice on the feasibility of appealing the decisionHowever, there is no guarantee that the outcome of the action will be in the interest of the Group Member Company in question if an appeal is madeCaution must be exercised when trading the Company's securities by shareholders and interested investorsIn the event of any significant development in these legal proceedings, the Company will make a separate announcementthis announcement is made in accordance with Rule 13.09 (1) of the Listing RulesAs disclosed in the 2007 Announcement, the group member company concerned is involved in the lawsuit brought by the plaintiff to the group member company concerned, alleging that the group member company concerned violated the relevant patent by submitting the sale, import and/or sale of L-Lysine products in the Netherlands, and that the court had issued the judgment, ruling that the group member company had infringed some of the relevant patents, but had not violated any trade secrets as the plaintiff allegedly didthe group member company concerned has appealed the judgement to the Court of Appeal of The HagueOn 7 April 2011, the Company received an English translation of the provisional decision of the Court of Appeal in The Hague dated 29 March 2011 and upheld the judgement pending a further non-trial hearing on legal costs, which is now scheduled for May 13, 2011The Board considered that the group member companies concerned had reason to appeal against the decision of the Court of Appeal of The HagueHowever, the Board is now seeking legal advice on the feasibility of appealing the decisionHowever, there is no guarantee that the outcome of the action will be in the interest of the Group Member Company in question if an appeal is made Caution must be exercised when trading the Company's securities by shareholders and interested investors ----------------------------------------------------------------------------------------- this announcement is made in accordance with section 13.09 (1) of the Securities Listing Rules of the Stock Exchange of Hong Kong Limited ("Listing Rules") hereby referring to the announcement made on 22 August 2007 by Dentons Biochemical Technology Group Limited ("the Company", together with its subsidiary, the Group) on 22 August 2007 (the "2007 Announcement") As disclosed in the 2007 Announcement, the Company and its other wholly owned subsidiaries ("relevant Group Member Companies") are involved in a project between Ajinomoto Co., Inc and Ajinomoto Eurolysine S.A.S ("Plaintiff") filed a lawsuit before the Local Court of The Hague on 15 May 2006 against the group member company concerned, according to which the group member company allegedly filed the sale, import and /or sale of its L-lysine products in the Netherlands, thereby infringing the Dutch part of the three European patents ("relevant patents") with the registration number of EP0.773 710 (entitled "Processfor Producing L-Lysine Fermentation"), EP0.733.712 (titled "Processfor Production Production SubstanceS)") and EP0.796.912 (titled "New Lysine deglutinase Gene and Procedure for the Production of L-Lysine( Novel Lysine Decarboxylase Gene and Processfor Producing L-Lysine) The Hague District Court issued a judgment in August 2007 ("The Judgment" ) finding that the group member companies concerned had infringed two relevant patents, patent numbers EP0.773.710 and EP0.733.712, but had not violated any trade secrets as the plaintiff had alleged The alleged infringement proceedings under patent number EP0.796.912 shall be adjourned pending a decision by the European Patent Office against the registration proceedings the group member company concerned has appealed the judgement to the Court of Appeal of The Hague On 7 April 2011, the Company received an English translation of the provisional ruling of the Court of Appeal in The Hague dated March 29, 2011, upholding the judgment on the infringement of two patents and suspending the proceedings pending further non-trial hearing son-in-law on legal costs, which is now scheduled for May 13, 2011 The alleged infringement proceedings under patent number EP0.796.912 will still have to be suspended pending a decision by the European Patent Office against the registration proceedings the Board of Directors (the Board of Directors) considers that the decision of the Hague Court of Appeal will not adversely affect the sale, financial or trade status and prospects of the Group as the Group has developed a bacterial variety of the same type of class that is different from the object of the action for the production of its L-lysine products and no longer uses the bacterial varieties involved in the proceedings to produce L-Lysine products the Board of Directors considered that the group member companies concerned had reason to appeal against the decision of the Court of Appeal of The Hague However, the Board is now seeking legal advice on the feasibility of appealing the decision However, there is no guarantee that the outcome of the action will be in the interest of the Group Member Company in question if an appeal is made Caution must be exercised when trading the Company's securities by shareholders and interested investors In the event of any significant development in these legal proceedings, the Company will make a separate announcement (name)